PATENT CLAIM ANALYSIS

Application Number: 16100120
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-02
Patent Classification: ["424", "093210"]

Abstract:
The present invention provides compositions comprising a protein expression blocker or PEBL comprising a target-binding molecule and localizing domain, and methods of using such compositions in cancer therapy. PEBLs are useful as a blockade of expression of target surface receptors (peptides or antigens) in immune cells. Also provided herein are CD3/TCRαβ-deficient T cells and CD3/TCRαβ-deficient chimeric antigen receptor T cells that express such PEBLs.

Claim (Index 92):
The engineered CD3/TCR\u03b1\u03b2-deficient CAR-T cell of  claim 87 , wherein the CAR binds CD3 or CD19.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 96.0
- Lexical Diversity: 1.4
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15821170', '15965739', '15419398', '15094674', '13979927']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7811145671342755
- 35 USC 102 Novelty (BERT): 0.6131117968910835
- Combined Prediction Score: 0.7643142901099563
- Mean Citation Score: 474.72279800000007
- Max Citation Score: 648.9918
- Similarity Product: 465.270764528668

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test